Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 538

1.

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.

Finer N, James WP, Kopelman PG, Lean ME, Williams G.

Int J Obes Relat Metab Disord. 2000 Mar;24(3):306-13.

PMID:
10757623
2.

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.

Diabetes Obes Metab. 2003 May;5(3):180-8.

PMID:
12681025
3.

A one-year trial to assess the value of orlistat in the management of obesity.

James WP, Avenell A, Broom J, Whitehead J.

Int J Obes Relat Metab Disord. 1997 Jun;21 Suppl 3:S24-30.

PMID:
9225173
4.

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M.

Lancet. 1998 Jul 18;352(9123):167-72.

PMID:
9683204
5.

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.

Diabetes Care. 1998 Aug;21(8):1288-94.

PMID:
9702435
6.

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.

Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group.

Int J Obes Relat Metab Disord. 2001 Nov;25(11):1713-21.

PMID:
11753595
7.

Orlistat in the long-term treatment of obesity in primary care settings.

Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR.

Arch Fam Med. 2000 Feb;9(2):160-7.

PMID:
10693734
8.

[Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].

Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H, Krempf M; European Multicenter Orlistat Study Group.

Ter Arkh. 2000;72(8):50-4. Russian.

PMID:
11019429
9.

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB.

JAMA. 1999 Jan 20;281(3):235-42. Erratum in: JAMA 1999 Apr 7;281(13):1174.

PMID:
9918478
10.

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P.

Diabetes Care. 2002 Jun;25(6):1033-41. Erratum in: Diabetes Care. 2003 Mar;26(3):971..

PMID:
12032111
11.

Treatment with orlistat reduces cardiovascular risk in obese patients.

Zavoral JH.

J Hypertens. 1998 Dec;16(12 Pt 2):2013-7.

PMID:
9886891
12.

Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.

Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.

Med Pregl. 1999 Sep-Oct;52(9-10):323-33. English, Croatian.

PMID:
10624380
14.

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

Diabetes Obes Metab. 2005 Nov;7(6):699-708.

PMID:
16219013
15.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
16.

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Aug;17(4):222-9.

PMID:
15575343
17.

Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group.

Van Gaal LF, Broom JI, Enzi G, Toplak H.

Eur J Clin Pharmacol. 1998 Apr;54(2):125-32.

PMID:
9626916
18.

Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns.

Karhunen L, Franssila-Kallunki A, Rissanen P, Valve R, Kolehmainen M, Rissanen A, Uusitupa M.

Int J Obes Relat Metab Disord. 2000 Dec;24(12):1567-72.

PMID:
11126207
19.

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.

Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J.

JAMA. 2005 Jun 15;293(23):2873-83. Erratum in: JAMA. 2005 Sep 28;294(12):1491.

PMID:
15956632
20.

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.

Jacob S, Rabbia M, Meier MK, Hauptman J.

Diabetes Obes Metab. 2009 Apr;11(4):361-71. doi: 10.1111/j.1463-1326.2008.00970.x. Epub 2009 Jan 22.

PMID:
19207292

Supplemental Content

Support Center